sunitinib
Commercial- Indications
- Gastrointestinal stromal tumor, Renal cell carcinoma, Pancreatic neuroendocrine tumor
Company intelligence / Profile preview
Shilpa Medicare has a strong commercial presence in generic APIs and formulations with multiple US FDA approvals. Its biosimilar division has launched adalimumab biosimilar and advanced several others to late-stage development. The company’s products are approved in the US, EU, India and other regulated markets.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shilpa Medicare.